Literature DB >> 16555280

Effects of drug resistance on viral load in patients failing antiretroviral therapy.

N Machouf1, R Thomas, V K Nguyen, B Trottier, M R Boulassel, M A Wainberg, J P Routy.   

Abstract

Previous studies on patients who develop drug resistant HIV-1 variants have shown that continued use of failing regimens might provide clinical benefit. However, the effect of long-term exposure to drug resistant variants may lead to emergence of compensatory mutations that may jeopardize this effect. In this study, we assess associations among type and number of drug resistant mutations, viral load and disease progression in patients with long-term follow up. Patients with genotypic testing performed at the time of treatment failure were enrolled. Comparison of viral load and CD4 cell count between different resistance groups was performed using analysis of variance. Multiple linear regression analysis was performed to assess the simultaneous effects of the presence of particular mutations and their accumulation on viral load. Data from 475 patients who were followed for a median of 43 months from October 1999 to July 2005 were studied. A "V shape" relationship was observed between the number of mutations and viral load. Specifically, in patients harboring up to five mutations, viral load was reduced by 0.8 log/copies when compared to wild-type variants. However, with more than six mutations viral load progressively increased. Certain reverse transcriptase mutations such as M184V/I, K70R, V108I, and protease mutations such as L33FIV, M84V, and M36I were associated with reduced viral load. Together, these findings suggest that long-term maintenance of a sub-optimal antiretroviral regimen may have deleterious consequences for the patient. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16555280     DOI: 10.1002/jmv.20582

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Smartphone-Based Mobile Detection Platform for Molecular Diagnostics and Spatiotemporal Disease Mapping.

Authors:  Jinzhao Song; Vikram Pandian; Michael G Mauk; Haim H Bau; Sara Cherry; Laurence C Tisi; Changchun Liu
Journal:  Anal Chem       Date:  2018-03-22       Impact factor: 6.986

2.  Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.

Authors:  Catherine Seyler; Christiane Adjé-Touré; Eugène Messou; Nicole Dakoury-Dogbo; François Rouet; Delphine Gabillard; Monica Nolan; Siaka Toure; Xavier Anglaret
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

3.  High HIV-1 Virological Failure and Drug Resistance among Adult Patients Receiving First-Line ART for At least 12 Months at a Decentralized Urban HIV Clinic Setting in Senegal before the Test-and-Treat.

Authors:  Aristid Ekollo Mbange; Abou Abdallah Malick Diouara; Halimatou Diop-Ndiaye; Ndèye Aminata Diaw Diouf; Ndèye Fatou Ngom-Ngueye; Kine Ndiaye Touré; Ahmed Dieng; Seynabou Lô; Mamadou Fall; Wilfred Fon Mbacham; Souleymane Mboup; Coumba Touré-Kane
Journal:  Infect Dis (Auckl)       Date:  2021-05-10

4.  Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Authors:  Nicole Ngo-Giang-Huong; Gonzague Jourdain; Billy Amzal; Pensiriwan Sang-a-gad; Rittha Lertkoonalak; Naree Eiamsirikit; Somboon Tansuphasawasdikul; Yuwadee Buranawanitchakorn; Naruepon Yutthakasemsunt; Sripetcharat Mekviwattanawong; Kenneth McIntosh; Marc Lallemant
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

5.  Discovery of a diaminoquinoxaline benzenesulfonamide antagonist of HIV-1 Nef function using a yeast-based phenotypic screen.

Authors:  Ronald P Trible; Purushottam Narute; Lori A Emert-Sedlak; John Jeff Alvarado; Katelyn Atkins; Laurel Thomas; Toshiaki Kodama; Naveena Yanamala; Vasiliy Korotchenko; Billy W Day; Gary Thomas; Thomas E Smithgall
Journal:  Retrovirology       Date:  2013-11-14       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.